Completed PHASE2 INTERVENTIONAL 2-arm NCT02942381

A Study of Hydroxychloroquine Sulfate for Reduction of Proteinuria in Patients With IgA Nephropathy

Sponsor: Peking University First Hospital

Conditions Hydroxychloroquine IgA Patients

Interventions Hydroxychloroquine Sulfate Placebo

Updated 7 times since 2017 Last updated: Feb 2, 2018 Started: Sep 13, 2016 Primary completion: Jan 8, 2018 Completion: Jan 8, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02942381, this PHASE2 trial focuses on Hydroxychloroquine and IgA Patients and remains completed. Sponsored by Peking University First Hospital, it has been updated 7 times since 2016, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Mar 2018 — Jun 2018 [monthly]

Completed PHASE2

Status: Recruiting → Completed
Jan 2017 — Mar 2018 [monthly]

Recruiting PHASE2

First recorded

Sep 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Peking University First Hospital

Data source: Peking University First Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China